[1]
|
von Scheven, E., Glidden, D.V. and Elder, M.E. (2002) Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis & Rheumatism, 47, 414-420.
doi:10.1002/art.10510
|
[2]
|
Espinosa, G., Cervera, R., Font, J. and Asherson, R.A. (2002) The lung in the antiphospholipid syndrome. Annals of the Rheumatic Diseases, 61, 195-198.
doi:10.1136/ard.61.3.195
|
[3]
|
Asherson, R.A., et al. (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore), 77, 195-207.
doi:10.1097/00005792-199805000-00005
|
[4]
|
Asherson, R.A. and Cervera, R. (1995) Review: Antiphospholipid antibodies and the lung. Journal of Rheumatology, 22, 62-66.
|
[5]
|
Cervera, R., et al. (2009) Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicenter prospective study of 1,000 patients. Annals of the Rheumatic Diseases, 68, 1428-1432.
|
[6]
|
Olivier, C., Blondiaux, E., Blanc, T., Borg, J.Y. and Dacher, J.N. (2006) Catastrophic antiphospholipid syndrome and pulmonary embolism in a 3-year-old child. Pediatric Radiology, 36, 870-873. doi:10.1007/s00247-006-0183-5
|
[7]
|
Porres-Aguilar, M., Pena-Ruiz, M.A., Burgos, J.D., Porres-Munoz, M. and Hughes, H.W. (2008) Chronic thromboembolic pulmonary hypertension as an uncommon presentation of primary antiphospholipid syndrome. Journal of the National Medical Association, 100, 734-736.
|
[8]
|
Espinosa, G., Bucciarelli, S., Asherson, R.A. and Cervera, R. (2008) Morbidity and mortality in the catastrophic antiphospholipid syndrome: Pathophysiology, causes of death, and prognostic factors. Seminars in Thrombosis and Hemostasis, 34, 290-294. doi:10.1055/s-0028-1082274
|
[9]
|
Tan, E.M., et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 25, 1271-1277.
doi:10.1002/art.1780251101
|
[10]
|
Hochberg, M.C. (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism, 40, 1725. doi:10.1002/art.1780400928
|
[11]
|
Petri, M. (2005) Review of classification criteria for systemic lupus erythematosus. Rheumatic Disease Clinics of North America, 31, 245-254.
doi:10.1016/j.rdc.2005.01.009
|
[12]
|
Gaubitz, M. and Schotte, H. (2005) Early diagnosis in patients with systemic lupus erythematosus (SLE). Zeitschrift für Rheumatologie, 64, 547-552.
doi:10.1007/s00393-005-0795-4
|
[13]
|
Gertner, E. and Lie, J.T. (1993) Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in primary antiphospholipid syndrome. Journal of Rheumatology, 20, 1224-1228.
|
[14]
|
Lim, W., Crowther, M.A. and Eikelboom, J.W. (2006) Management of antiphospholipid antibody syndrome: A systematic review. JAMA, 295, 1050-1057.
doi:10.1001/jama.295.9.1050
|
[15]
|
Crowther, M.A., et al. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New England Journal of Medicine, 349, 1133-1138. doi:10.1056/NEJMoa035241
|
[16]
|
Ruiz-Irastorza, G., Hunt, B.J. and Khamashta, M.A. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis & Rheumatism, 57, 1487-1495. doi:10.1002/art.23109
|
[17]
|
Castro, P., et al. (2003) Catastrophic antiphospholipid syndrome and acute heart failure. Report of a case. Revista Medica de Chile, 131, 1037-1041.
doi:10.4067/S0034-98872003000900010
|
[18]
|
Huang, H.J., Wang, J.N., Tsai, Y.C., Lin, C.S. and Wu, J.M. (2002) Intrapulmonary thrombolytic therapy in a child with acute pulmonary embolism due to primary antiphospholipid syndrome. Acta Paediatrica Taiwanica, 43, 351-353.
|
[19]
|
Kim, W.J., Hong, Y.K. and Yoo, W.H. (2008) Epidural hematoma mimicking transverse myelitis in a patient with primary antiphospholipid syndrome. Rheumatology International, 28, 709-712. doi:10.1007/s00296-007-0512-5
|
[20]
|
Ordi-Ros, J., Perez-Peman, P. and Monasterio, J. (1994) Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies). Haemostasis, 24, 165-174.
|
[21]
|
Cherian, J. and Gertner, E. (2005) Recurrent pulmonary embolism despite inferior vena cava filter placement in patients with the antiphospholipid syndrome. Journal of Clinical Rheumatology, 11, 56-58.
doi:10.1097/01.rhu.0000152150.01274.1b
|
[22]
|
Zifman, E., Rotman-Pikielny, P., Berlin, T. and Levy, Y. (2009) Insertion of inferior vena cava filters in patients with the antiphospholipid syndrome. Seminars in Arthritis and Rheumatism, 38, 472-477.
|
[23]
|
Palareti, G., et al. (2006) D-dimer testing to determine the duration of anticoagulationtherapy. New England Journal of Medicine, 355, 1780-1789.
doi:10.1056/NEJMoa054444
|